This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sen, D Articles by Keen, R W Search for Related Content PubMed PubMed Citation Articles by Sen, D Articles by Keen, R W Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CALCIUM COMPOUNDS CALCIUM, ELEMENTAL Medline Plus Health Information Lupus Osteoporosis Social Bookmarking                   What's this?

Osteoporosis in systemic lupus erythematosus: prevention and treatment

Metabolic Bone Disease Unit, Royal National Orthopaedic Hospital, Stanmore, UK

R W Keen

Department of Medicine, University College London, London, UK; Metabolic Bone Disease Unit, Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex, HA7 4LP, UK richard.keen{at}ucl.ac.uk

The patient with systemic lupus erythematosus (SLE) is at risk of osteoporosis through several factors: the inflammatory disease itself, disease-related co-morbidity, and its treatment. Bone loss is apparent early in the disease and this may be confounded primarily by treatment with corticosteroids. Patients should be assessed for additional risk factors for osteoporosis and general lifestyle measures adopted. Bone mineral density measurement should be considered in SLE patients at high risk of osteoporosis, particularly those starting corticosteroids and in postmenopausal women. Calcium and vitamin D supplementation provide general prophylaxis and are a suitable first-line option. Hormone replacement should be used in hypogondal subjects unless contra-indicated. In subjects at high fracture risk, particularly in postmenopausal women, bisphosphonate therapy should be considered as these agents have been shown to significantly reduce vertebral fracture risk. These measures should reduce the burden of osteoporosis and fracture in patients with lupus.

Key Words: osteoporosis • fracture • bisphosphonates • calcium • vitamin D

Lupus, Vol. 10, No. 3, 227-232 (2001)
DOI: 10.1191/096120301671413439


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C C Mok, A Mak, and K M Ma Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus Lupus, February 1, 2005; 14(2): 106 - 112. [Abstract] [PDF]

				Y Ioannou and D A Isenberg Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge Postgrad. Med. J., October 1, 2002; 78(924): 599 - 606. [Abstract] [Full Text] [PDF]